Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TTFRCTK)

• DTT Name: CREB-binding protein (CREBBP) DTT Info
• Gene Name: CREBBP

Molecule-Related Drug & Molecule List

4 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
C 82	DMEWXFK	Scleroderma	4A42	Phase 1/2	[1]
CCS1477	DM9UZM1	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[2]
PRI-724	DM0HTEF	Acute myeloid leukaemia	2A60	Phase 1/2	[3]
FT-7051	DMCK3OI	Prostate cancer	2C82.0	Phase 1	[4]

1 Patented Agent(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Pyrrolo-pyrrolone derivative 6	DMBW208	N. A.	N. A.	Patented	[5]

3 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
I-CBP112	DMQX3W6	Discovery agent	N.A.	Investigative	[6]
ischemin	DMM2I9G	Discovery agent	N.A.	Investigative	[7]
SGC-CBP30	DMTLRGZ	Discovery agent	N.A.	Investigative	[8]

References

• [1] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [2] Targeting the p300/CBP Axis in Lethal Prostate Cancer. Cancer Discov. 2021 May;11(5):1118-1137.
• [3] Inhibition of Wnt/beta-catenin/CREB binding protein (CBP) signaling reverses pulmonary fibrosis. Proc Natl Acad Sci U S A. 2010 Aug 10;107(32):14309-14.
• [4] Clinical pipeline report, company report or official report of FORMA Therapeutics.
• [5] BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22.
• [6] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2734).
• [7] A small molecule binding to the coactivator CREB-binding protein blocks apoptosis in cardiomyocytes. Chem Biol. 2011 Apr 22;18(4):531-41.
• [8] Bromodomains and their pharmacological inhibitors. ChemMedChem. 2014 Mar;9(3):438-64.